Division of Hematology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Semin Perinatol. 2018 Mar;42(2):122-128. doi: 10.1053/j.semperi.2017.12.008. Epub 2018 Jan 12.
Despite advances made in technology and neonatal intensive care, the rate of hemorrhagic and thrombotic complications remains unacceptably high in patients undergoing extracorporeal membrane oxygenation (ECMO) and these complications negatively impact morbidity and mortality. Management of anticoagulation in neonates who have a developing hemostatic system is vastly different from adults and poses unique challenges. Variation in practice among ECMO centers regarding anticoagulation monitoring and titration reflects the lack of high-quality evidence. Novel anticoagulants may offer alternative options, though their impact on outcomes is yet to be demonstrated. In this chapter, we review the hemostatic alterations that occur during ECMO with a focus on current approaches and limitations to anticoagulation titration in neonates on ECMO.
尽管在技术和新生儿重症监护方面取得了进展,但在接受体外膜氧合 (ECMO) 的患者中,出血和血栓并发症的发生率仍然高得令人无法接受,这些并发症对发病率和死亡率产生负面影响。正在发育中的止血系统的新生儿的抗凝管理与成人有很大的不同,并且带来了独特的挑战。ECMO 中心在抗凝监测和滴定方面的实践差异反映了缺乏高质量证据。新型抗凝剂可能提供替代选择,但其对结局的影响仍有待证明。在这一章中,我们回顾了 ECMO 期间发生的止血变化,重点介绍了目前 ECMO 新生儿抗凝滴定的方法和局限性。